regulator of G protein signaling 1Genealiases: 1R20 · BL34 · HEL-S-87 · IER1 · IR20
Q-omics provides the consensus-scored RGS1 profile across patient tissues and cancer cell-line models. RGS1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RGS1 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, RGS1 RNA expression shows 15,499 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight ACC, KIRC, and LSCC as cancer lineages where RGS1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RGS1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RGS1 survival associations across molecular data types. RGS1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RGS1 RNA expression–survival associations across cancer types. High RGS1 expression shows unfavorable associations in ACC, UVM, LGG and STAD, but favorable associations in HNSC and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RGS1 RNA expression.
This table summarizes RGS1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for RGS1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RGS1 shows lower tumor expression in BLCA and COAD and higher tumor expression in KIRC, KIRP, STAD and BRCA. The KIRC box plot shows higher RGS1 RNA expression in tumor versus normal tissue (log2 FC = +3.385, t-test p < 0.001).
This table shows molecular features associated with RGS1 in patient tissues and cancer cell lines. In patient samples, RGS1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, RGS1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
